Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDF-FTC PrEP pharmacology in Kenyan cisgender women
PACTR202311518894272Phase 2Unknown
- Sponsor
- University of Washington
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tenofovir disoproxil fumarate and emtricitabine in human immunodeficiency virus infection (HIV) (4 arms), sponsored by University of Washington. Primary endpoint: Benchmark concentrations of TFV-DP in DBS and PBMCs. Status: unknown.
02
Drugs
tenofovir disoproxil fumarateemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202311518894272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202311518894272.